-
公开(公告)号：US08968392B2
公开(公告)日：2015-03-03
申请号：US13561828
申请日：2012-07-30
申请人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.
摘要翻译： 一种抑制血管内膜增生的方法，包括：将支架放置在血管内，所述支架具有圆柱形构造的支架主体，其外表面和内表面具有涂覆在其上的金刚石状薄膜，第一涂层涂层 至少支架体的外表面，第一涂层由包含生物可降解聚合物和一种血管内膜增生抑制剂的第一组合物制成，其包含不抑制内皮细胞增殖的阿加曲班，其重量组成比 血管内膜增生抑制剂的聚合物在8:2至7:3的范围内，以及第二涂层; 并使阿加曲班从支架释放，从而抑制血管内膜增生而不抑制内皮细胞的增殖。
-
公开(公告)号：US20130018455A1
公开(公告)日：2013-01-17
申请号：US13561828
申请日：2012-07-30
申请人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A method of inhibiting vascular intimal hyperplasia including: placing a stent within a blood vessel, the stent having a stent body of a cylindrical configuration having outer and inner surfaces with a diamond-like thin film coated on the surfaces, a first coated layer coating at least the outer surface of the stent body, the first coated layer being prepared of a first composition comprising a biodegradable polymer and a vascular intimal hyperplasia inhibitor of a kind, comprising argatroban, which does not inhibit proliferation of endothelial cells, the weight composition ratio of the polymer to the vascular intimal hyperplasia inhibitor being within the range of 8:2 to 7:3, and a second coated layer; and causing argatroban to be released from the stent to thereby inhibit the vascular intimal hyperplasia without inhibiting proliferation of endothelial cells.
摘要翻译： 一种抑制血管内膜增生的方法，包括：将支架放置在血管内，所述支架具有圆柱形构造的支架主体，其外表面和内表面具有涂覆在其上的金刚石状薄膜，第一涂层涂层 至少支架体的外表面，第一涂层由包含生物可降解聚合物和一种血管内膜增生抑制剂的第一组合物制成，其包含不抑制内皮细胞增殖的阿加曲班，其重量组成比 血管内膜增生抑制剂的聚合物在8:2至7:3的范围内，以及第二涂层; 并使阿加曲班从支架释放，从而抑制血管内膜增生而不抑制内皮细胞的增殖。
-
公开(公告)号：US20100249914A1
公开(公告)日：2010-09-30
申请号：US12801307
申请日：2010-06-02
申请人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
摘要翻译： 支架包括具有外表面和内表面的圆柱形构造的支架体，至少涂覆外表面的第一涂层，以及基本上完全覆盖在第一涂层上的第二涂层涂层。 第一涂层由包含不抑制内皮细胞增殖的聚合物和血管内膜增生抑制剂（优选阿加曲班）的第一组合物制备，聚合物与抑制剂的重量组成比在该范围内 8：2到3：7。 另一方面，第二涂层由单独的聚合物或包含聚合物和药物的第二组合物制备，所述药物与所述聚合物的80重量％的重量组成比小于20重量％。
-
公开(公告)号：US08591571B2
公开(公告)日：2013-11-26
申请号：US13137560
申请日：2011-08-25
申请人： Ikuo Omura , Zhen Yu Jin
发明人： Ikuo Omura , Zhen Yu Jin
CPC分类号： A61F2/91 , A61F2210/0076 , A61F2250/0067 , A61L31/08 , A61L31/10 , A61L31/16 , C08L67/04
摘要： A drug-eluting stent comprises a coated layer prepared of a composition comprising a polymer and a drug, the coated layer being a single coated layer with the composition, or comprises a first coated layer prepared of the above composition and a second coated layer with a polymer alone, the first coated layer being coated by the second coated layer. The drug is a vascular intimal hyperplasia inhibitor which does not inhibit proliferation of endothelial cells, and the composition substantially excludes a lipid-soluble low-molecular compound. The polymer in the first layer is a copolymer of lactic acid (monomer A) and a terminal hydroxy straight alkyl carboxylic acid having 3 to 8 carbon atoms, and, if the second coated layer is formed, the polymer in the second coated layer is a poly(lactic acid), a poly(glycolic acid), or a poly(lactic acid-co-glycolic acid).
摘要翻译： 药物洗脱支架包括由包含聚合物和药物的组合物制备的涂层，涂层是具有组合物的单一涂层，或包含由上述组合物制备的第一涂层，以及第二涂层，其具有 单独的聚合物，第一涂层被第二涂层涂覆。 该药物是不抑制内皮细胞增殖的血管内膜增生抑制剂，其组成基本上不含脂溶性低分子化合物。 第一层中的聚合物是具有3-8个碳原子的乳酸（单体A）和末端羟基直链烷基羧酸的共聚物，并且如果形成第二涂层，则第二涂层中的聚合物是 聚（乳酸），聚（乙醇酸）或聚（乳酸 - 共 - 乙醇酸）。
-
公开(公告)号：US20120310329A1
公开(公告)日：2012-12-06
申请号：US13492290
申请日：2012-06-08
申请人： Ikuo OMURA , Zhen Yu JIN , Shuzo YAMASHITA , Hiroo IWATA , Akira MOCHIZUKI
发明人： Ikuo OMURA , Zhen Yu JIN , Shuzo YAMASHITA , Hiroo IWATA , Akira MOCHIZUKI
IPC分类号： A61F2/82
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
摘要翻译： 支架包括具有外表面和内表面的圆柱形构造的支架体，至少涂覆外表面的第一涂层，以及基本上完全覆盖在第一涂层上的第二涂层涂层。 第一涂层由包含不抑制内皮细胞增殖的聚合物和血管内膜增生抑制剂（优选阿加曲班）的第一组合物制备，聚合物与抑制剂的重量组成比在该范围内 8：2到3：7。 另一方面，第二涂层由单独的聚合物或包含聚合物和药物的第二组合物制备，所述药物与所述聚合物的80重量％的重量组成比小于20重量％。
-
公开(公告)号：US20110313514A1
公开(公告)日：2011-12-22
申请号：US13137560
申请日：2011-08-25
申请人： Ikuo Omura , Zhen Yu Jin
发明人： Ikuo Omura , Zhen Yu Jin
IPC分类号： A61F2/82
CPC分类号： A61F2/91 , A61F2210/0076 , A61F2250/0067 , A61L31/08 , A61L31/10 , A61L31/16 , C08L67/04
摘要： A drug-eluting stent comprises a coated layer prepared of a composition comprising a polymer and a drug, the coated layer being a single coated layer with the composition, or comprises a first coated layer prepared of the above composition and a second coated layer with a polymer alone, the first coated layer being coated by the second coated layer. The drug is a vascular intimal hyperplasia inhibitor which does not inhibit proliferation of endothelial cells, and the composition substantially excludes a lipid-soluble low-molecular compound. The polymer in the first layer is a copolymer of lactic acid (monomer A) and a terminal hydroxy straight alkyl carboxylic acid having 3 to 8 carbon atoms, and, if the second coated layer is formed, the polymer in the second coated layer is a poly(lactic acid), a poly(glycolic acid), or a poly(lactic acid-co-glycolic acid).
摘要翻译： 药物洗脱支架包括由包含聚合物和药物的组合物制备的涂层，涂层是具有组合物的单一涂层，或包含由上述组合物制备的第一涂层，以及第二涂层，其具有 单独的聚合物，第一涂层被第二涂层涂覆。 该药物是不抑制内皮细胞增殖的血管内膜增生抑制剂，其组成基本上不含脂溶性低分子化合物。 第一层中的聚合物是具有3-8个碳原子的乳酸（单体A）和末端羟基直链烷基羧酸的共聚物，并且如果形成第二涂层，则第二涂层中的聚合物是 聚（乳酸），聚（乙醇酸）或聚（乳酸 - 共 - 乙醇酸）。
-
公开(公告)号：US08641756B2
公开(公告)日：2014-02-04
申请号：US13492290
申请日：2012-06-08
申请人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
IPC分类号： A61F2/82
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
摘要翻译： 支架包括具有外表面和内表面的圆柱形构造的支架体，至少涂覆外表面的第一涂层，以及基本上完全覆盖在第一涂层上的第二涂层涂层。 第一涂层由包含不抑制内皮细胞增殖的聚合物和血管内膜增生抑制剂（优选阿加曲班）的第一组合物制备，聚合物与抑制剂的重量组成比在该范围内 8：2到3：7。 另一方面，第二涂层由单独的聚合物或包含聚合物和药物的第二组合物制备，所述药物与所述聚合物的80重量％的重量组成比小于20重量％。
-
公开(公告)号：US08409272B2
公开(公告)日：2013-04-02
申请号：US12733460
申请日：2008-09-03
申请人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
IPC分类号： A61F2/82
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
摘要翻译： 支架包括具有外表面和内表面的圆柱形构造的支架体，至少涂覆外表面的第一涂层，以及基本上完全覆盖在第一涂层上的第二涂层涂层。 第一涂层由包含不抑制内皮细胞增殖的聚合物和血管内膜增生抑制剂（优选阿加曲班）的第一组合物制备，聚合物与抑制剂的重量组成比在该范围内 8：2到3：7。 另一方面，第二涂层由单独的聚合物或包含聚合物和药物的第二组合物制备，所述药物与所述聚合物的80重量％的重量组成比小于20重量％。
-
公开(公告)号：US20100198344A1
公开(公告)日：2010-08-05
申请号：US12733460
申请日：2008-09-03
申请人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
发明人： Ikuo Omura , Zhen Yu Jin , Shuzo Yamashita , Hiroo Iwata , Akira Mochizuki
IPC分类号： A61F2/82 , B05D3/00 , A61K31/4709 , A61P7/00
CPC分类号： A61F2/82 , A61F2/91 , A61F2/915 , A61F2002/91541 , A61F2250/0067 , A61K9/0024 , A61L31/10 , A61L31/16 , A61L2300/416 , A61L2300/608 , A61L2420/08
摘要： A stent includes a stent body of a cylindrical configuration having outer and inner surfaces, a first coated layer coating at least the outer surface, and a second coated layer coating substantially completely over the first coated layer. The first coated layer is prepared of a first composition comprising a polymer and a vascular intimal hyperplasia inhibitor (preferably argatroban) of a kind, which does not inhibit proliferation of endothelial cells, the weight compositional ratio of the polymer to the inhibitor being within the range of 8:2 to 3:7. On the other hand, the second coated layer is prepared of a polymer alone or a second composition comprising a polymer and a drug, the weight compositional ratio of the drug to 80% by weight of the polymer being less than 20% by weight.
摘要翻译： 支架包括具有外表面和内表面的圆柱形构造的支架体，至少涂覆外表面的第一涂层，以及基本上完全覆盖在第一涂层上的第二涂层涂层。 第一涂层由包含不抑制内皮细胞增殖的聚合物和血管内膜增生抑制剂（优选阿加曲班）的第一组合物制备，聚合物与抑制剂的重量组成比在该范围内 8：2到3：7。 另一方面，第二涂层由单独的聚合物或包含聚合物和药物的第二组合物制备，所述药物与所述聚合物的80重量％的重量组成比小于20重量％。
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.019 秒)
